LON:GSK - GlaxoSmithKline Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 1,512.60 +11.00 (+0.73 %)
(As of 03/19/2019 02:26 AM ET)
Previous CloseGBX 1,501.60
Today's RangeGBX 1,500.60 - GBX 1,516
52-Week RangeGBX 1,269.80 - GBX 1,648.80
Volume5.23 million shs
Average Volume9.12 million shs
Market Capitalization£74.42 billion
P/E Ratio20.75
Dividend Yield6.10%
BetaN/A
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology; and strategic alliance with Merck KGaA to jointly develop and commercialize M7824 (bintrafusp alfa), an investigational bifunctional fusion protein immunotherapy. GlaxoSmithKline plc also has a joint research collaboration with Fimbrion Therapeutics Inc. to develop a small molecule candidate for the treatment and prevention of urinary tract infections. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-80475000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£30.82 billion
Cash FlowGBX 92.47 per share
Book ValueGBX 88.60 per share

Profitability

Miscellaneous

EmployeesN/A
Outstanding Shares4,919,989,760
Market Cap£74.42 billion
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable

GlaxoSmithKline (LON:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the London Stock Exchange (LON) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a dividend on Wednesday, February 6th. Investors of record on Thursday, February 21st will be given a dividend of GBX 23 per share on Thursday, April 11th. This represents a dividend yield of 1.49%. The ex-dividend date is Thursday, February 21st. This is a positive change from GlaxoSmithKline's previous dividend of $19.00. The official announcement can be viewed at this link. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (LON:GSK) released its earnings results on Wednesday, April, 25th. The company reported $24.60 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $24.30 by $0.30. View GlaxoSmithKline's Earnings History.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for GlaxoSmithKline.

What price target have analysts set for GSK?

18 analysts have issued 12 month target prices for GlaxoSmithKline's shares. Their forecasts range from GBX 41.74 to GBX 1,900. On average, they anticipate GlaxoSmithKline's share price to reach GBX 1,518.15 in the next year. This suggests a possible upside of 0.4% from the stock's current price. View Analyst Price Targets for GlaxoSmithKline.

What is the consensus analysts' recommendation for GlaxoSmithKline?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 2 sell ratings, 11 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.

Has GlaxoSmithKline been receiving favorable news coverage?

Headlines about GSK stock have been trending negative this week, according to InfoTrie. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. GlaxoSmithKline earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of GlaxoSmithKline's key competitors?

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include General Electric (GE), Intel (INTC), Lloyds Banking Group (LLOY), Vodafone Group (VOD), Bank of America (BAC), AstraZeneca (AZN), BP (BP), AT&T (T), Pfizer (PFE) and Johnson & Johnson (JNJ).

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:
  • Ms. Emma Walmsley, CEO & Director (Age 49)
  • Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)
  • Mr. Jack Bailey, Pres of US Pharmaceuticals
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 58)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)

How do I buy shares of GlaxoSmithKline?

Shares of GSK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately GBX 1,512.60.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of £74.42 billion and generates £30.82 billion in revenue each year.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is http://www.gsk.com/.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom. The company can be reached via phone at +44-20-80475000.


MarketBeat Community Rating for GlaxoSmithKline (LON GSK)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  881 (Vote Outperform)
Underperform Votes:  1,424 (Vote Underperform)
Total Votes:  2,305
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/19/2019 by MarketBeat.com Staff

Featured Article: Current Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel